Medical

Magazine articles on health care providers, pharmaceutical companies, and medical technology.

Old Articles: <Older 1321-1330 Newer>

The Motley Fool July 22, 2004 Charly Travers	Patience With MedImmune While MedImmune has one of the top-selling biologic drugs in the industry, the growth in revenues and earnings is a bit sluggish for what many biotech investors are looking for.
The Motley Fool July 22, 2004 Nathan Slaughter	VISX Eyes Future The vision-correction firm posts triple-digit earnings growth, capturing the attention of investors.
The Motley Fool July 22, 2004 Brian Gorman	Stability for Covance? After a solid quarter, the drug development service company may have found a way to keep revenue consistent.
The Motley Fool July 21, 2004 Brian Gorman	Novartis Shows the Way It may be a model for other pharmaceutical outfits looking to improve productivity.
The Motley Fool July 21, 2004 Brian Gorman	Will Cholesterol Drug Pack a Punch? Merck's and Schering-Plough's new combination may receive a lukewarm welcome. In the near term, investors will probably cheer both companies, but in the long run, the companies will be better off it they can come up with something totally original.
The Motley Fool July 20, 2004 Brian Gorman	Bayer Reshuffles Business Bayer, one of Germany's most venerable industrial names, is revamping its house. Seemingly in one fell swoop, the company is spinning off its Lanxess chemicals and polymers unit and buying Roche's over-the-counter-drugs business.
The Motley Fool July 20, 2004 Rich Duprey	Lasers Lose Focus Dental-equipment manufacturer Biolase reports flat sales.
The Motley Fool July 19, 2004 W.D. Crotty	Gold Mine Cave-In? Will recalls involving the Taxus stent mar the future earnings of Boston Scientific?
The Motley Fool July 19, 2004 Brian Gorman	Medicare Revises Stance on Obesity Medicare has added its two cents to the national conversation on the U.S.'s obesity problem, and its new policy has potentially important implications for many pharmaceutical companies.
BusinessWeek July 26, 2004 Amy Barrett	Hooked On The Cash From Cholesterol Cholesterol-lowering drugs are massive moneyspinners. But can big pharmaceutical companies sidestep expiring patents?
<Older 1321-1330 Newer> Return to current articles.